KBC Group
IRON icon

KBC Group’s Disc Medicine IRON Stock Holding History

KBC Group’s Portfolio IRON Stock Details IRON Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$65K Hold
1,011
– – ﹤0.01% 1552
2025
Q4 		$80K Buy
+1,011
New +$85.4K ﹤0.01% 1427

Other funds holding IRON

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

KBC Group's IRON Position: Q1 2026 in Review

KBC Group held its Disc Medicine (IRON) position steady in Q1 2026 at 1,011 shares worth $65K. The position accounts for ﹤0.01% of the portfolio, ranked #1552.

KBC Group first reported a position in IRON in Q4 2025 and has held it in 2 quarters since. The position peaked at $80K in Q4 2025. 203 funds tracked by Wall St. Rank hold IRON as of Q1 2026.

  • KBC Group held 1,011 shares of Disc Medicine worth $65K as of Q1 2026.
  • KBC Group left its Disc Medicine share count unchanged in Q1 2026.
  • Disc Medicine made up ﹤0.01% of KBC Group's portfolio in Q1 2026, its #1552 holding.
  • KBC Group first reported a position in Disc Medicine in Q4 2025 and has held it in 2 quarters since.
  • KBC Group's Disc Medicine position peaked at $80K in Q4 2025.
  • 203 funds tracked by Wall St. Rank held Disc Medicine as of Q1 2026.

Based on KBC Group's 13F filing for Q1 2026, filed 7 May 2026.